文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases.

作者信息

Liu Xiaocui, Mei Fengjun, Fang Mei, Jia Yaqiong, Zhou Yazhu, Li Chenxi, Tian Panpan, Lu Chufan, Li Guangrui

机构信息

Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Department of Neurology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.

出版信息

Front Oncol. 2024 Jan 10;13:1322635. doi: 10.3389/fonc.2023.1322635. eCollection 2023.


DOI:10.3389/fonc.2023.1322635
PMID:38269023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10806520/
Abstract

BACKGROUND: Brain metastases (BM), including brain parenchyma metastases (BPM) and leptomeningeal metastases (LM), are devastating metastatic complications in advanced cancer patients. Next-generation sequencing (NGS) is emerging as a new promising tool for profiling cancer mutation, which could facilitate the diagnosis of cancer. This retrospective study aimed to investigate the molecular genetic characteristics of non-small cell lung cancer (NSCLC) patients with BPM and LM using NGS. METHODS: Cerebrospinal fluid (CSF) samples and paired plasma samples were collected from 37 patients of NSCLC-BM. We profiled genetic mutation characteristics using NGS from NSCLC-BM by comparing CSF circulating tumour DNA (ctDNA) with plasma ctDNA and primary tumour tissues. RESULTS: Among the 37 patients with NSCLC-BM, 28 patients had LM with or without BPM, while 9 patients only had BPM. Driver and drug-resistant mutations in primary tumours with LM included: L858R (10, 35.7%), 19del (6, 21.4%), L858R+ (1, 3.6%), L858R+S768I (1, 3.6%), (2, 7.1%), (1, 3.6%), negative (5, 17.9%), and unknown (2, 7.1%). In patients with NSCLC-LM, the detection rate and abundance of ctDNA in the CSF were significantly higher than those in paired plasma. The main driver mutations of NSCLC-LM remained highly consistent with those of the primary tumours, along with other unique mutations. Circulating tumour DNA was negative in the CSF samples of BPM patients. Patients with BMP had a higher ratio of 19del than L858R mutation (55.6% vs 11.1.%), whereas NSCLC patients with LM had a higher ratio of L858R than 19del mutation (50.0% vs 25.0%). Most patients with positive plasma ctDNA results were male ( = 0.058) and in an unstable state ( = 0.003). CONCLUSION: Our study indicated that the CSF ctDNA detected by NGS may reflect the molecular characteristics and heterogeneity of NSCLC-LM. Timely screening of patients with NSCLC for CSF ctDNA, especially for patients with positive plasma ctDNA, may facilitate the early detection of LM. Furthermore, patients with the 19del may have a higher risk of developing BPM.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/b53e06ec3542/fonc-13-1322635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/e267ca151967/fonc-13-1322635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/6f84013a0bee/fonc-13-1322635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/78d337d63573/fonc-13-1322635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/b53e06ec3542/fonc-13-1322635-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/e267ca151967/fonc-13-1322635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/6f84013a0bee/fonc-13-1322635-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/78d337d63573/fonc-13-1322635-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d395/10806520/b53e06ec3542/fonc-13-1322635-g004.jpg

相似文献

[1]
Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases.

Front Oncol. 2024-1-10

[2]
Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.

Clin Neurol Neurosurg. 2023-2

[3]
Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.

J Neurooncol. 2023-10

[4]
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.

Thorac Cancer. 2023-5

[5]
Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution.

Heliyon. 2022-12-16

[6]
[Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].

Zhongguo Fei Ai Za Zhi. 2020-8-20

[7]
Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.

Thorac Cancer. 2020-3

[8]
Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.

Heliyon. 2023-10-8

[9]
Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.

Curr Cancer Drug Targets. 2019

[10]
Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.

Front Oncol. 2022-4-28

引用本文的文献

[1]
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review.

Transl Lung Cancer Res. 2025-3-31

[2]
Leptomeningeal Disease: Current Approaches and Future Directions.

Curr Neurol Neurosci Rep. 2025-3-18

[3]
Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression.

Cancers (Basel). 2025-3-1

[4]
Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.

J Neurooncol. 2025-3

本文引用的文献

[1]
Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer.

Sci Rep. 2022-12-26

[2]
Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.

Heliyon. 2022-7-19

[3]
Review of Current Principles of the Diagnosis and Management of Brain Metastases.

Front Oncol. 2022-5-24

[4]
Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.

Front Oncol. 2022-4-28

[5]
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.

Front Oncol. 2022-3-15

[6]
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.

J Thorac Oncol. 2022-6

[7]
Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance.

Discov Oncol. 2021-11-8

[8]
The evolving landscape of sex-based differences in lung cancer: a distinct disease in women.

Eur Respir Rev. 2022-3-31

[9]
Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022.

Nucleic Acids Res. 2022-1-7

[10]
The Genome Sequence Archive Family: Toward Explosive Data Growth and Diverse Data Types.

Genomics Proteomics Bioinformatics. 2021-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索